If nothing else, it puts BP on notice that they are not the only avenue to getting Brilacidin (IBD) to commercialization. Never hurts to have competing sources of capital vying for a treasured drug platform. Besides value, it also puts the timeline on a quicker pace because if BP wants to continue to drag their heels, they may end up with squat.